The Indianapolis-based pharmaceutical giant hopes to enroll up to 400 people in a study to see if its drug baricitinib can treat patients with severe cases of Covid-19.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,